Hepatitis C news from FierceBiotech
NewsVertex shares rise on positive data for telaprevir
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
Tercica shares skyrocket following takeover bid
Moving fast, investors swiftly bid up the value of Tercica's stock yesterday afternoon after hearing that France's Ipsen would pay $9 a share to acquire all the stock in the company it didn't already Read more...
First miRNA drug enters human studies
Denmark's Santaris has kicked off a Phase I study of SPC3649, a potential treatment for hepatitis C infection. The trial marks the first time a microRNA drug has been tested in humans. SPC3649 will Read more...
Valeant chops workforce in restructuring
In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its Read more...
ALSO NOTED: Isotechnika reports psoriasis success; Romark enrolls hep C patients; and much more...
> Isotechnika's ISA247 has demonstrated significant efficacy against psoriasis. Report > Romark Laboratories Read more...
Vertex shares jump on positive telaprevir data
Vertex Pharmaceuticals got a much-needed boost to its share price after investors responded positively to the latest data analysis on its closely-watched hepatitis C therapy. Vertex stock jumped 28 Read more...
C&L: Opexa CEO to retire
GeoVax Labs has added Dr. Robert McNally as president and CEO. Opexa Therapeutics announced that David McWilliams, president and CEO, will retire following the naming of his successor. Synthetic Read more...
Presidio snags preclinical hep C program for $108M
XTL Biopharmaceuticals is pocketing a $4 million upfront fee and stands to earn another $104 million in milestones after inking a collaboration deal with Read more...
ALSO NOTED: Rumor Mill: AstraZeneca a possible Shire suitor; Cardiome baits hook for partners; Vertex shares keep sliding; and
> Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. Read more...
| Press ReleasesPRESS RELEASE: Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Read more... PRESS RELEASE: OctoPlus presents positive Phase IIa study results for Locteron in hepatitis C at AASLD conference OctoPlus presents positive Phase IIa study results for Locteron in hepatitis C at AASLD conference OctoPlus, the drug delivery and development company, announces that full and complete results from Read more... |
Get more Hepatitis C coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends